Scancell Holdings plc, (‘Scancell’ or the ‘Company’) the developer of novel immunotherapies for the treatment of cancer, is pleased to announce the publication of a peer-reviewed research paper in the
Wealth Manager at Shard Capital Stockbrokers, Simon Niven, provides some insights into the small pharmaceutical company sector.
Synairgen (LSE: SNG), the respiratory drug discovery and development company, today announces an update to its collaboration agreement with Pharmaxis and the Lysyl Oxidase type 2 (LOXL2) programme. Following the
ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, is pleased to announce it has conditionally raised £1.0 million of gross proceeds through the issue of 80,000,000 new ordinary shares
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion
